APOE rs7694381: The Christchurch Variant and Alzheimer's Resilience
The rs7694381 variant in the APOE gene, commonly referred to as the Christchurch mutation (p.Arg166Gln or R136S), is a rare genetic change. It has gained significant scientific attention for its potential to confer resistance to the development of Alzheimer's disease pathology, even in individuals at high genetic risk.
What each genotype means
Typical APOE variant profile
This genotype represents the common, non-Christchurch form of the APOE gene. It does not carry the specific Christchurch mutation associated with potential resistance to Alzheimer's disease pathology in clinical case studies.
This is the most common genotype, found in the vast majority of the global population.
Potential protective variant carrier
This genotype includes one copy of the APOE Christchurch variant (p.Arg166Gln). Research in families with inherited early-onset Alzheimer's disease suggests that carrying even one copy of this variant may be associated with a delayed onset of symptoms.
This genotype is extremely rare, occurring in less than 0.01% of the global population.
Potential protective variant carrier
This genotype includes two copies of the APOE Christchurch variant (p.Arg166Gln). Clinical observations have suggested that this variant may confer resistance to Alzheimer's disease pathology, potentially delaying the onset of cognitive impairment by decades in individuals predisposed to early-onset forms of the disease.
This genotype is exceptionally rare, found in significantly less than 0.01% of the global population.
Understanding the Variant and Its Location
The variant rs7694381 is a single nucleotide polymorphism (SNP) located within the APOE gene. In scientific literature, this specific mutation is frequently identified as the Christchurch variant, characterized by an amino acid substitution where arginine is replaced by serine at position 136 (often cited as R136S). This position is critical to the structure and function of the Apolipoprotein E protein. Because this variant is located in a gene already heavily implicated in neurodegenerative health, researchers have focused on how this specific change alters the protein's interaction with other molecules in the brain. While many variants in APOE are studied for their role in increasing disease risk, rs7694381 is notable for its potential protective properties, making it a subject of intense investigation in the field of molecular neurology.
The Role of the APOE Gene
The APOE gene provides instructions for making a protein called apolipoprotein E. This protein is a primary component of lipoproteins, which are particles that carry fats, including cholesterol, through the bloodstream. In the brain, APOE is the main cholesterol carrier and plays a vital role in lipid transport and the maintenance of neuronal health. It is also involved in the clearance of amyloid-beta, a protein that forms plaques in the brains of individuals with Alzheimer's disease. Because APOE is so central to brain metabolism and the inflammatory response, variations in this gene can significantly influence how the brain handles stress and damage. The Christchurch variant is thought to modify these standard functions, potentially by altering how APOE binds to heparan sulfate proteoglycans, which may in turn influence the accumulation of tau proteins and the brain's immune response.
Research and Evidence Strength
The evidence supporting the protective nature of the rs7694381 variant is currently based on clinical case studies and preclinical research. The variant was famously identified in a woman from a large family in Colombia who carried a mutation for early-onset Alzheimer's disease but remained cognitively healthy for decades. Subsequent research using mouse models has shown that the R136S mutation can attenuate tau pathology and modulate microglial responses to amyloid plaques. While these findings are compelling, the evidence strength is considered limited because it relies heavily on specific case reports and animal models rather than large-scale human clinical trials. Scientists are currently using these insights to develop therapeutic antibodies that mimic the protective effects of the Christchurch variant. It is important to note that while this research is promising, it is still in the experimental stage and does not yet translate into clinical treatments for the general public.
Population Frequency
The rs7694381 variant is extremely rare in global populations. According to data from large-scale genomic databases like gnomAD, the frequency of this specific allele is well below 0.01%. Because it is so uncommon, it is not typically included in standard commercial genetic testing panels. Its rarity makes it difficult to conduct large-scale population studies to confirm its protective effects across diverse ancestral backgrounds. Most of the current understanding of this variant comes from studying specific families or individuals who carry the mutation, rather than observing its distribution in the general population. Consequently, the vast majority of people do not carry this variant, and its absence does not imply any specific health risk or lack of resilience.
What This Information Means for You
If you are curious about your own genetic makeup, it is important to understand that the rs7694381 variant is not a standard marker tested in routine medical or direct-to-consumer genetic reports. This information is primarily used in academic and clinical research settings to understand the biological mechanisms of Alzheimer's disease. You cannot use this information to diagnose yourself or predict your personal risk for neurodegenerative conditions. Genetic associations are complex, and the presence or absence of a single variant does not determine your health outcomes. If you have concerns about Alzheimer's disease, cognitive decline, or your family history, the most appropriate step is to consult with a healthcare provider or a genetic counselor. They can provide personalized guidance based on your medical history and current clinical standards, rather than relying on individual genetic markers found in research literature.
How common is this variant?
The rs7694381 variant is extremely rare in global populations, with a frequency of less than 0.01% in gnomAD.
Frequently asked questions
Is the Christchurch variant a cure for Alzheimer's?
No, the Christchurch variant is not a cure. It is a rare genetic mutation that has been observed to correlate with delayed onset of symptoms in specific individuals, but it is not a treatment for those who already have the disease.
Can I get tested for the rs7694381 variant?
This variant is not typically included in standard clinical or commercial genetic tests. Because it is extremely rare and primarily of interest in research, it is not used for routine diagnostic purposes.
Does having the Christchurch variant mean I will never get Alzheimer's?
Not necessarily. While the variant is associated with resilience in case studies, genetics is only one factor in Alzheimer's disease. Other lifestyle, environmental, and genetic factors also play significant roles.
How are researchers using this variant to help patients?
Researchers are studying the biological mechanism of the Christchurch variant to develop new therapies. They are creating antibodies that mimic the protective effects of the variant to potentially reduce tau tangles and improve brain health in patients.
Sources & further reading
Educational information only, last refreshed 9/24/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7694381?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in APOE
Variant in the APOE/TOMM40 locus associated with late-onset Alzheimer's disease risk.
Downstream variant in the APOE region associated with lipid metabolism profiles and healthspan indicators.
Upstream regulatory variant influencing APOE transcription and plasma lipid modulation.
Defines the APOE ε2 allele, associated with lower LDL cholesterol and reduced risk of Alzheimer's disease.
Regulatory variant in the APOE promoter region modulating transcriptional activity and risk for late-onset neurodegeneration.
Variant in the APOE gene cluster strongly associated with low-density lipoprotein cholesterol levels and altered susceptibility to cardiovascular disease.